NM heute noch unter 1100 und morgen ...

bzw. am Montag unter 1000 ...
das nennt man auch galoppierente Schwinsucht ...
lol

haut weg dire Scheisse ... alles muss raus ..
ob ihr wollt oder nicht ...

solong best invest

LALA !!!

realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" />

Float: 15.08M (Institutions1: 52.80%) 2$ monday after institution selloff


Shares Outstanding5: 16.02M
Float: 15.08M
% Held by Insiders1: 4.38%
% Held by Institutions1: 52.80%
Shares Short (as of May 28, 2010)3: 44.58K
Short Ratio (as of May 28, 2010)3: 0.80
Short % of Float (as of May 28, 2010)3: N/A

ih.advfn.com/...d=staticchart&s=N%5ENMTI&p=5&t=15" style="max-width:560px" />

realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" />

hab schon 3x gekauft...heute !

Posted by: sigsmoke    Date: Thursday, June 17, 2010 11:06:49 PM  
In reply to: momentum74 who wrote msg# 32  Post # of 46      

NMTI has a float of only 15.32M of which 59% of shares are held by institutions, mutual funds, and insiders. That leaves approx. 6M shares for retail. finance.yahoo.com/q/mh?s=NMTI+Major+Holders

The news posted today was not all that bad IMO and NMTI has many other products in the pipeline along with ongoing clinical studies. I can see this jumping back up rather quickly from where it closed today. The AH trading being an indication with over 1M shares traded and a 20% recovery.

I think just buying pressure tomorrow from day/swing traders could move this to the .80-1.00 easily.

Hold even longer and you can reap the rewards of some positive PR's that will be made when NMTI's RT2 Delivery System is launched throughout Europe in the next few months.


investorshub.advfn.com/boards/read_msg.aspx?message_id=51434617

Nmt Medical Inc. (MM (NASDAQ:NMTI)
Last Price (USD) $0.7409
Change  0.1809 (32.30%)
Bid 0.7409
Ask 0.76
Volume 7,924,560
Days Range 0.6199 - 0.8399
Last Trade 6/18/2010 12:58:33 PM

10mill cash 15 mill shares...

seekingalpha.com/instablog/...versold-after-closure-trial-data

Dieser Hotstock wurde heute vor Handelsbeginn von den HH-Analysten als kurz-bis mittelfristig interessanter Kandidat empfohlen.
Hier die Präsentation!

"NMTI Hot Stock
NMTI - US6292941092

stockcharts.com/h-sc/ui?s=nmti

NMTI hatte gestern 15 Minuten vor Handelsschluss diese PR veröffentlicht, in der bekannt gegeben wurde, dass eine medizinische Testreihe zu "CLOSURE I PFO/Stroke" nicht komplett bis zum Ende durchgeführt werden konnte:
finance.yahoo.com/news/...unces-bw-153973274.html?x=0&.v=1

"The preliminary results of CLOSURE I data analysis indicate that the trial did not achieve its primary endpoint: to demonstrate that treatment by device closure with the STARFlex® technology is superior to the current best medical therapy for preventing recurrent strokes and TIAs. However, the preliminary results indicate that closure with STARFlex® provided a small, but not statistically significant, benefit over current best medical therapy."

Die Folge war ein urplötzlicher Selloff unter Rekordvolumen (4,065,224 shares) - die Aktie schloss -78% auf $0,58.

NMTI hat zusätzlich einige andere klinische Studien in der Pipeline, die Potenzial für zukünftig positive News bieten - hier eine Übersicht:
www.snl.com/IRWebLinkX/GenPage.aspx?IID=4148066&GKP=202520

Zudem ist die Aktienstruktur für einen NASDAQ-stock sehr attraktiv:
A/S: 30,000,000 shares
O/S: 16,058,319 shares (31.03.2010)

Kurzfristig kann es noch zu weiteren Kursverlusten kommen - mittelfristig aber sehen wir hier spekulativ interessantes Reboundpotenzial!

NMTI ist auch in Frankfurt handelbar - dort fehlt es aber meist an relvantem Volumen, daher sollten Spekulationswillige den US-Börsenplatz bevorzugen."

http://www.snl.com/IRWebLinkX/GenPage.aspx?IID=4148066&GKP=202520

bigcharts.marketwatch.com/charts/...;rand=1762&mocktick=1" style="max-width:560px" />

bigcharts.marketwatch.com/charts/...p;rand=1762&mocktick=1

www.finviz.com/...hx?t=NMTI&ty=c&ta=1&p=d&s=l" style="max-width:560px" />

What comes down goes up !

In addition, we should note that the results of CLOSURE I have no impact on the status of our current FDA and CE Mark approvals for ventricular septal defect (VSD) and atrial level shunt patients

 

#000000 1px solid">Trademark	#000000 1px solid">	#000000 1px solid">Jurisdiction	#000000 1px solid">	#000000 1px solid">Status	#000000 1px solid">	#000000 1px solid">Renewal Date
At The Heart of Brain Attacks™		Canada		Pending		—
At The Heart of Brain Attacks®		European Community		Registered		Sep 2015
At The Heart of Brain Attacks™		United States		Allowed		—
BioSTAR®		Canada		Registered		Jun 2024
BioSTAR®		European Community		Registered		Apr 2014
BioSTAR®		Japan		Registered		Oct 2015
BioSTAR®		United States		Registered		Jun 2016
BioTREK™		Canada		Allowed		—
BioTREK™		European Community		Pending		—
BioTREK®		Japan		Registered		Feb 2016
BioTREK™		United States		Pending		—
CardioSEAL®		United States		Registered		Jan 2018
Gator™		Canada		Pending		—
Gator®		European Community		Registered		Apr 2014
Gator®		Japan		Registered		Sep 2017
Gator™		United States		Allowed		—
NMT Medical®		Canada		Registered		Jan 2018
NMT Medical®		United States		Registered		Apr 2011
Rapid Transport		European Community		Registered		Aug 2013
STARFlex®		Canada		Registered		Sep 2020
STARFlex®		European Community		Registered		Feb 2011
STARFlex®		Japan		Registered		Jun 2014
STARFlex®		United States		Registered		Aug 2012

In addition, we are the exclusive licensee within specific fields of use to several technologies. We are the exclusive licensee under certain patents, expiring from 2012 to 2015, relating to the CardioSEAL®, STARFlex®, and BioSTAR® cardiac septal repair implants, delivery systems and methods for repairing cardiac and vascular defects. We are the exclusive licensee to a patent used in nitinol septal repair devices which expires in 2011. We believe the near expiration of these patents is not likely to have a significant impact on our business. We are also the exclusive licensee under certain patents, expiring from 2014 to 2019, related to the intestinal collagen layer utilized in our BioSTAR® device and under certain patents, expiring from 2010 to 2023, related to the novel bioabsorbable polymer utilized in our BioTREK™ device.

We also rely on trade secrets and technical know-how in the development and manufacture of our devices, which we seek to protect, in part, through confidentiality agreements with our employees, consultants and other parties. We have eight trademarks, four of which are registered with the United States Patent and Trademark Office (see the following table).

savpride.com/wordpress/wp-content/uploads/...cer_animated.gif" style="max-width:560px" />

..wissen wir mehr!

img684.imageshack.us/img684/9887/rocket04june.gif

-/-

Da scheint sich ja die Mannschaft einig zu sein!!! :-)

HiddenGemStocks.com offers a free newsletter on various active stocks on all major exchanges in the U.S.A. and in Canada. To date thousands of our subscribers grow their portfolios daily by using our services. Join us today at HiddenGemStocks.com and watch your account size grow!!!

Disclaimer:

The assembled information disseminated by HiddenGemStocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. HiddenGemStocks.com does expect that investors will buy and sell securities based on information assembled and presented on HiddenGemStocks.com site and/or newsletter. PLEASE always do your own due diligence, and consult your financial advisor.

Contact Information:
hiddengemstocks
Adam Garcia
Tel: 407-405-1474
Email us

http://emailwire.com/release/...MWE-SMOD-NMT-Medical-Inc-HCP-AGU.html

NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures. NMT is currently investigating with its CLOSURE I clinical trial, the potential connection between a common heart defect that allows a right-to-left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right-to-left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 32,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology.

Stroke is a leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and an additional 500,000 Americans experience a TIA.

For more information about NMT Medical, please visit cts.businesswire.com/ct/...5=5aedd0bb5d1ba5c47bcc655463a88c1a.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed under the heading “Risk Factors” included in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, Quarterly Report on Form 10-Q for the period ended March 31, 2010, and subsequent filings with the U.S. Securities and Exchange Commission.



Contact:
NMT Medical, Inc.Richard Davis, 617-737-0930Chief Operating Officer

finance.yahoo.com/news/...apid-bw-2095920926.html?x=0&.v=1